RxDoctor Payments Data

Hina Doshi, MD

Internal Medicine · Clawson, MINPI 1508857715

Payments from drug & device makers

$1,312in general payments, 2019–2025

Across 58 payments — averaging $22.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$373
  • Pfizer$151
  • Terumo Medical Corporation$143
  • Amgen$126
  • Lilly USA, LLC$125
  • Medtronic$77
  • plus $317 from 10 others

What the payments were for

  • Food & beverage$1,312100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,312 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$35,583
Medicare patients
76
Services billed
499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide41$46,518
EliquisApixaban20$24,781
TradjentaLinagliptin16$23,135
JardianceEmpagliflozin19$19,162
Atorvastatin Calcium222$2,301
Lidocaine14$1,780
Metoprolol Succinate83$1,639
Levothyroxine Sodium97$1,322
Albuterol Sulfate HfaAlbuterol Sulfate34$1,296
Omeprazole92$1,097
Lisinopril103$1,061
Rosuvastatin Calcium99$1,050
Ezetimibe41$1,042
Montelukast Sodium56$981
Amlodipine Besylate106$880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$373$46,51841 claims
Boehringer IngelheimTradjenta, Jardiance$32$42,29735 claims
PfizerEliquis$151$24,78120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Clawson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →